Regeneron: Antibody cocktail cut COVID-19 death risk in half for hospitalized patients
Tarrytown's Regeneron presented some promising data Tuesday from its antibody cocktail.
According to its own research, the company's antibody cocktail cut the risk of death by 50% in patients currently in the hospital that require low-flow oxygen.
Initial data showed it had to be used in non-hospitalized patients only.
Last month, the FDA granted an emergency-use authorization for the antibody cocktail.